Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment
(2015) In Acta Oncologica 54(10). p.1770-1780- Abstract
- Purpose. To investigate if testicular cancer survivors (TCSs) have a higher incidence of work loss compared with the population, accounting for stage, treatment and relapse.Material and methods. A cohort of 2146 Swedish TCSs diagnosed 1995-2007 (seminoma n = 926, non-seminoma n = 1220) was identified in the SWENOTECA (Swedish-Norwegian Testicular Cancer Group) register, and matched 1:4 to population comparators. Prospectively recorded work loss data (both before and after diagnosis) were obtained from national registers through September 2013. Adjusted relative risks (RR) and 95% confidence intervals (CI) of sick leave and/or disability pension were calculated annually and overall with Poisson- and Cox regression, censoring at relapse. The... (More)
- Purpose. To investigate if testicular cancer survivors (TCSs) have a higher incidence of work loss compared with the population, accounting for stage, treatment and relapse.Material and methods. A cohort of 2146 Swedish TCSs diagnosed 1995-2007 (seminoma n = 926, non-seminoma n = 1220) was identified in the SWENOTECA (Swedish-Norwegian Testicular Cancer Group) register, and matched 1:4 to population comparators. Prospectively recorded work loss data (both before and after diagnosis) were obtained from national registers through September 2013. Adjusted relative risks (RR) and 95% confidence intervals (CI) of sick leave and/or disability pension were calculated annually and overall with Poisson- and Cox regression, censoring at relapse. The mean number of annual work days lost was also estimated.Results. TCSs were at a modestly increased annual risk of work loss up to the third year of follow-up (RR3rd year 1.25, 95% CI 1.08, 1.43), attributed to a more pronounced risk among extensively treated patients (4 chemotherapy courses: RR3rd year 1.60, 95% CI 1.19, 2.15; > 4 courses: RR3rd year 3.70, 95% CI 2.25, 6.11). Patients on surveillance or limited treatment (radiotherapy, 1-3 chemotherapy courses) did not have an increased risk of work loss beyond the first year. TCSs receiving > 4 chemotherapy courses had higher mean number of annual days of work loss up to the 10th year post-diagnosis, and a five-fold risk of disability pension (RR 5.16, 95% CI 2.00, 10.3).Conclusion. Extensively treated TCSs, but not those on surveillance or limited treatment, are at increased risk of work loss long-term, not explained by relapse. These patients may benefit from early rehabilitation initiatives. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8555592
- author
- Nord, Carina ; Olofsson, Sven-Erik LU ; Glimelius, Ingrid ; Cedermark, Gabriella Cohn ; Ekberg, Sara ; Cavallin-Ståhl, Eva LU ; Neovius, Martin ; Jerkeman, Mats LU and Smedby, Karin E.
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Oncologica
- volume
- 54
- issue
- 10
- pages
- 1770 - 1780
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000366669900010
- scopus:84946203417
- pmid:25833328
- ISSN
- 1651-226X
- DOI
- 10.3109/0284186X.2015.1020967
- language
- English
- LU publication?
- yes
- id
- 9d446c58-f49d-420d-8243-efc33e25965c (old id 8555592)
- date added to LUP
- 2016-04-01 12:57:49
- date last changed
- 2022-03-06 03:00:49
@article{9d446c58-f49d-420d-8243-efc33e25965c,
abstract = {{Purpose. To investigate if testicular cancer survivors (TCSs) have a higher incidence of work loss compared with the population, accounting for stage, treatment and relapse.Material and methods. A cohort of 2146 Swedish TCSs diagnosed 1995-2007 (seminoma n = 926, non-seminoma n = 1220) was identified in the SWENOTECA (Swedish-Norwegian Testicular Cancer Group) register, and matched 1:4 to population comparators. Prospectively recorded work loss data (both before and after diagnosis) were obtained from national registers through September 2013. Adjusted relative risks (RR) and 95% confidence intervals (CI) of sick leave and/or disability pension were calculated annually and overall with Poisson- and Cox regression, censoring at relapse. The mean number of annual work days lost was also estimated.Results. TCSs were at a modestly increased annual risk of work loss up to the third year of follow-up (RR3rd year 1.25, 95% CI 1.08, 1.43), attributed to a more pronounced risk among extensively treated patients (4 chemotherapy courses: RR3rd year 1.60, 95% CI 1.19, 2.15; > 4 courses: RR3rd year 3.70, 95% CI 2.25, 6.11). Patients on surveillance or limited treatment (radiotherapy, 1-3 chemotherapy courses) did not have an increased risk of work loss beyond the first year. TCSs receiving > 4 chemotherapy courses had higher mean number of annual days of work loss up to the 10th year post-diagnosis, and a five-fold risk of disability pension (RR 5.16, 95% CI 2.00, 10.3).Conclusion. Extensively treated TCSs, but not those on surveillance or limited treatment, are at increased risk of work loss long-term, not explained by relapse. These patients may benefit from early rehabilitation initiatives.}},
author = {{Nord, Carina and Olofsson, Sven-Erik and Glimelius, Ingrid and Cedermark, Gabriella Cohn and Ekberg, Sara and Cavallin-Ståhl, Eva and Neovius, Martin and Jerkeman, Mats and Smedby, Karin E.}},
issn = {{1651-226X}},
language = {{eng}},
number = {{10}},
pages = {{1770--1780}},
publisher = {{Taylor & Francis}},
series = {{Acta Oncologica}},
title = {{Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment}},
url = {{https://lup.lub.lu.se/search/files/11247049/3074637.pdf}},
doi = {{10.3109/0284186X.2015.1020967}},
volume = {{54}},
year = {{2015}},
}